Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2017-11-14 Director's Dealing
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Appendix 3X - McCann 2 pages 58.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shareholdings and options, and notes the director's appointment date. The content focuses on disclosure of personal share transactions and holdings by a company director. The document length is 2750 characters, which is relatively short and specific to director dealings. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). Therefore, the correct classification is DIRS.
2017-11-14 English
Appendix 3X - Kluge 2 pages 58.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, including shareholdings and contractual interests related to the director. The document is a formal notification of a director's personal share transactions and interests, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, not financial results or management changes. Therefore, the appropriate classification is Director's Dealing (DIRS).
2017-11-14 English
Appendix 3X - Buck 2 pages 58.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, including shareholdings and personal interests. This type of document is a report of personal share transactions or interests by company directors. It is not an annual report, earnings release, or any other financial or regulatory filing. The document length is short and focused solely on director interests, matching the definition of Director's Dealing filings.
2017-11-14 English
Appendix 3X - Behrenbruch 2 pages 56.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held directly or indirectly, and states the date of appointment of the director. The content is focused on disclosure of personal shareholdings by a company director, which aligns with insider trading or director dealings reporting requirements. There is no financial performance data, management discussion, or other report content. The document length is short (2318 characters) and is a formal notification of director's share interests. Therefore, the document fits the category of Director's Dealing (DIRS).
2017-11-14 English
ASX Notice - Admission and Quotation 3 pages 263.3KB
Capital/Financing Update Classification · 95% confidence The document is an official notice from ASX regarding the admission and commencement of official quotation of Telix Pharmaceuticals Limited on the ASX. It details the listing date, share offer, escrowed shares, and trading timetable. There is no financial report, earnings data, or management discussion. The document is an announcement about the company's listing and capital raising, which fits the category of Capital/Financing Update (CAP). The document length is 3501 characters, which is short but contains substantive information about the capital raising and listing, not just a report publication announcement. Therefore, the best classification is CAP with high confidence.
2017-11-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.